Author Correction: A nanoengineered topical transmucosal cisplatin delivery system induces anti-tumor response in animal models and patients with oral cancer

Goldberg, Manijeh; Manzi, Aaron; Birdi, Amritpreet; LaPorte, Brandon; Conway, Peter; Cantin, Stefanie; Mishra, Vasudha; Singh, Alka; Pearson, Alexander T.; Goldberg, Eric; Goldberger, Sam; Flaum, Benjamin; Hasina, Rifat; London, Nyall R.; Gallia, Gary L.; Bettegowda, Chetan; Young, Simon; Sandulache, Vlad C.; Melville, James C.; Shun, Jonathan; O’Neill, Sonya E.; Aydin, Erkin; Zhavoronkov, Alex; Vidal, Anxo; Soto, Atenea; Alonso, María José; Rosenberg, Ari J.; Lingen, Mark W.; D’Cruz, Anil; Agrawal, Nishant; Izumchenko, Evgeny

doi:10.1038/s41467-022-35449-1

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nanoscale encapsulation and drug delivery of chemotherapeutic agents present viable opportunities that offset poor drug solubility, tissue biodistribution, circulation half-life, toxicity, and chemical instability liabilities for enhanced drug action. − Chitosan-derived nanoparticles, produced by copolymer grafting of hydrophilic polymers such as polyethylene glycol (PEG) unto cationic chitosan, enable the creation of biocompatible materials with tunable properties toward multifunctional nanodevices. , This offers an iterative platform for smart integration of targeting groups and therapeutics to improve selective drug accumulation, limit premature clearance, and unveil novel applications in theranostics, bioadhesion, wound healing, and stimulus-responsive polymer engineering. Chitosan-derived nanoparticles represent a well-established technology that has been applied in local and systemic delivery as well as therapeutic targeting.…”

Section: Introductionmentioning

confidence: 99%

Auranofin-Loaded Chitosan Nanoparticles Demonstrate Potency against Triple-Negative Breast Cancer

Afrifa,

Kim,

Pitton

et al. 2024

ACS Appl. Bio Mater.

View full text Add to dashboard Cite

Triple-negative breast cancer (TNBC) remains a clinical challenge due to molecular, metabolic, and genetic heterogeneity as well as the lack of validated drug targets. Thus, therapies or delivery paradigms are needed. Gold-derived compounds including the FDA-approved drug, auranofin have shown promise as effective anticancer agents against several tumors. To improve the solubility and bioavailability of auranofin, we hypothesized that the nanodelivery of auranofin using biodegradable chitosan modified polyethylene glycol (PEG) nanoparticles (NPs) will enhance anticancer activity against TNBC by comparing the best nanoformulation with the free drug. The selection of the nanoformulation was based on synthesis of various chitosan PEG copolymers via formaldehyde-mediated engraftment of PEG onto chitosan to form [chitosan-g-PEG] copolymer. Furthermore, altered physiochemical properties of the copolymer was based on the formaldehyde ratio towards nanoparticles (CP 1−4 NPs). Following the recruitment of PEG onto the chitosan polymer surface, we explored how this process influenced the stiffness of the nanoparticle using atomic force microscopy (AFM), a factor crucial for in vitro and in vivo studies. Our objective was to ensure the full functionality and inherent properties of chitosan as the parent polymer was maintained without allowing PEG to overshadow chitosan's unique cationic properties while improving solubility in neutral pH. Hence, CP 2 NP was chosen. To demonstrate the efficacy of CP 2 NP as a good delivery carrier for auranofin, we administered a dose of 3 mg/kg of auranofin, in contrast to free auranofin, which was given at 5 mg/kg. In vivo studies revealed the potency of encapsulated auranofin against TNBC cells with a severe necrotic effect following treatment superior to that of free auranofin. In conclusion, chitosan-g-PEG nanoparticles have the potential to be an excellent delivery system for auranofin, increasing its effectiveness and potentially reducing its clinical limitations.

show abstract